Results 251 to 260 of about 4,166,507 (358)

Improving the Process of New Drug Development

, 1991
Helen Glenny
openalex   +1 more source

An efficient strategy for producing RNA‐free Nucleocapsid protein of SARS‐CoV‐2 for biochemical and structural investigations

FEBS Open Bio, EarlyView.
Cleavable N‐terminal Thioredoxin fusion enabled soluble expression and purification of otherwise insoluble SARS‐CoV‐2 Nucleocapsid (N) protein. A four‐step purification strategy yielded highly homogeneous, RNA‐free N protein. Binding assays showed high RNA affinity (Kd ~ 28 nm). The study will facilitate high‐resolution structural studies of N protein,
Shweta Singh, Gagan D. Gupta
wiley   +1 more source

New antifungal strategies and drug development against WHO critical priority fungal pathogens. [PDF]

Front Cell Infect Microbiol
Li Y, Liu Y, Jiang Y, Yang Y, Ni W, Zhang W, Tan L.   +6 more
europepmc   +1 more source

DEVELOPMENT OF A NEW NON-SURGICAL PERFUSION TECHNIQUE TO EVALUATE NASAL DRUG DELIVERY

, 1991
Polireddy Dondeti
openalex   +2 more sources

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

FEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash, Campbell W. Gourlay, Ina Oehme, Michelle D. Garrett, Jindrich Cinatl Jr, Mark N. Wass, Martin Michaelis   +6 more
wiley   +1 more source

Over-the-counter drug development in developing countries.

Indian J Pharmacol
Bharati V, Rajaram S, Prakash A, Medhi B.   +3 more
europepmc   +1 more source

A father's crusade in rare disease drug development: a case study of Elpida therapeutics and Melpida. [PDF]

Orphanet J Rare Dis
Portero D, Xu Q, Hussain A, Lo AW.
europepmc   +1 more source

Development of high-performance frontal analysis and its application to the study of the drug-protein binding sites.

, 1991
Terumichi Nakagawa, Akimasa Shibukawa
openalex   +2 more sources

Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo

FEBS Open Bio, EarlyView.
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu, Yan Tao, Shan Wu, Yuwen Gong, Youli Zhao, Shaomin Niu, Hui Cheng, You Mu, Na Xu, Ying Wang, Jianzhong Lu, Shanhui Liu, Lanlan Li   +12 more
wiley   +1 more source

The Hsp90β Isoform: An Attractive Target for Drug Development. [PDF]

Med Res Rev
Chaudhury S, D'Amico T, Blagg BSJ.
europepmc   +1 more source